The FDA has approved GlaxoSmithKline's Arexvy, the first-ever vaccine in the US to prevent lower respiratory tract disease due to respiratory syncytial virus in individuals aged 60 and older. "We expect this to be a tremendously important vaccine both for public health and for the company," said Phil Dormitzer, GSK's global head of vaccines R&D.